Immune effects of thymosin alpha-1 for stage I lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether thymosin alpha-1, an immune-boosting medicine, can help people with stage I non-small cell lung cancer after surgery. The goal is to see if it improves the immune system's response and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage I non-small cell lung cancer that can be removed with surgery
- You are having a type of lung surgery called lobectomy, with removal of nearby lymph nodes
- You have not had any other cancer in the past and do not currently have another cancer
- You have not received any cancer treatments or immune-stimulating drugs before
- You are between 18 and 75 years old
- You are healthy enough for surgery, with good organ function (heart, lungs, liver, kidneys, brain)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial looks at whether thymosin-alpha 1, an immune-support treatment, can help prevent colon cancer from coming back after surgery. It targets people with high-risk stage II or III colon cancer who have had the tumor removed.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.